Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Aug 15;7(8):2304-8.
eCollection 2014.

Cytokeratin 19, thyroperoxidase, HBME-1 and galectin-3 in evaluation of aggressive behavior of papillary thyroid carcinoma

Zeming Liu  1 , Xiaoyu Li  1 , Lan Shi  1 , Yusufu Maimaiti  1 , Tianwen Chen  1 , Zhi Li  1 , Shuntao Wang  1 , Yiquan Xiong  1 , Hui Guo  1 , Wenshan He  1 , Chunping Liu  1 , Xiu Nie  2 , Wen Zeng  3 , Tao Huang  1
Affiliations

Cytokeratin 19, thyroperoxidase, HBME-1 and galectin-3 in evaluation of aggressive behavior of papillary thyroid carcinoma

Zeming Liu et al. Int J Clin Exp Med. .

Abstract

Objective: To assess usefulness of cytokeratin 19 (CK19), thyroperoxidase (TPO), Hector Battifora mesothelial epitope-1 (HBME-1) and galectin-3 (GAL3) in evaluation of aggressive behavior of PTCs.

Methods: All available clinical and pathological data were reviewed in 168 papillary thyroid cancer patients; while the values as predictive markers of PTC were tested by univariate and multivariate analysis.

Results: According to the univariate set of tests, positive expression of CK19 and negative expression of TPO correlated significantly with total tumor diameter (P < 0.05); But there was no association of positive CK19 expression and negative expression of TPO with gender, age, capsular invasion or lymph node metastasis. Moreover, there was no association of positive HBME-1 and galectin-3 expression with clinical aggressive behavior of PTCs.

Conclusion: High expression of CK19 and negative expression of TPO indicate total tumor diameter of PTC, but expression of CK19, TPO, HBME-1 and GAL3 has no values in the identification of PTCs with other potentially aggressive behavior.

Keywords: CK19; HBME-1; TPO; aggressive behavior; galectin-3; papillary thyroid carcinoma.

PubMed Disclaimer

References

    1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295:2164–2167. - PubMed
    1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300. - PubMed
    1. de Matos PS, Ferreira AP, de Oliveira Facuri F, Assumpcao LV, Metze K, Ward LS. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology. 2005;47:391–401. - PubMed
    1. Saussez S, Glinoer D, Chantrain G, Pattou F, Carnaille B, Andre S, Gabius HJ, Laurent G. Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. Thyroid. 2008;18:705–712. - PubMed
    1. Cheng S, Serra S, Mercado M, Ezzat S, Asa SL. A high-throughput proteomic approach provides distinct signatures for thyroid cancer behavior. Clin Cancer Res. 2011;17:2385–2394. - PubMed

LinkOut - more resources